A Clinical Study of Intravaginal Prasterone (Intrarosa®) in Postmenopausal Vulvovaginal Atrophy

Lee's Pharmaceutical logo

Lee's Pharmaceutical

Status and phase

Active, not recruiting
Phase 3


Postmenopausal Vulvovaginal Atrophy


Drug: intravaginal prasterone
Drug: Placebo ovules

Study type


Funder types




Details and patient eligibility


This study is a phase III which includes two treatment phases. The phase 1 study is a multi-center, randomized, double-blind, placebo- controlled, parallel group that provide primary efficacy and safety data. The Phase 2 study is a single-arm, open-label conducted in a subset of subjects who completed the phase 1 study to provid additional long-term safety and efficacy.

Full description

The phase 1 study which includes the screening phase (up to 3 weeks) and treatment phase (12 weeks). After signing the informed consent, the inclusion and exclusion criteria will be confirmed preliminarily at screening visit and reconfirmed at Day 1 (baseline). At least 418 eligible subjects will be randomized in a 1:1 ratio to receive 6.5mg of intravaginal prasterone or placebo once-daily for 12 weeks. The phase 2 study which includes the treatment phase (26 weeks). A total of 100 subjects who have completed Phase 1, not occur adverse event(AE) grade ≥3 or serious adverse event (SAE), or recover all AE grades ≤1, and voluntary to participate in Phase 2 study. After signing the ICF, the subject will receive 6.5mg of intravaginal for 26 weeks.


418 estimated patients




40 to 80 years old


No Healthy Volunteers

Inclusion criteria

Subject is between 40 and 80 years of age inclusive;

Menopausal women (with or without hysterectomy) must also meet 1 of the following 3 conditions:

A Non-hysterectomy, menopause ≥ 12 months; B. Menopause > 6 months and < 12 months or premenopausal hysterectomy, follicle stimulating hormone (FSH) > 40 IU/L; C ≥ 6 months since baseline assessment (Day 1) with or without hysterectomy.

  • At screening and baseline (Day 1), the subject presented with moderate-severe dyspareunia (dyspareunia) as measured by the Vaginal Atrophy Symptom Questionnaire (VASQ) and self-rated as the most bothersome symptom.
  • ≤ 5% superficial cells by vaginal smear at screening and baseline (Day 1).
  • Vaginal pH > 5 at Screening and Baseline (Day 1).
  • Women (with or without a partner) who currently have sex or other sexual activity (masturbation, etc.) at least once a month, or who have sex or other sexual activity at least once a month in the past, with reduced sexual activity due to excessive pain or vaginal dryness.
  • Normal physical examination of the breast and normal mammographic findings (BI-RADS grade 1 or 2) within 9 months prior to the baseline visit (Day 1).
  • Normal cervical smear results (including inflammatory changes), regardless of hysterectomy (no abnormal cervical smear in the past 2 years if ASCUS is present, and human papillomavirus (HPV) test negative can be used) within 12 months before the baseline visit (Day 1).

Voluntarily participate in this clinical trial and sign the informed consent form (ICF).


Exclusion criteria

  • Patients with a history of malignant tumor.
  • Have active or history of thromboembolic disease (excluding thromboembolic events due to accidents, surgery, immobilization).
  • Clinically significant endocrine metabolic disease (e.g., diabetes mellitus) not controlled with medication.
  • Use of estrogen injections, estrogen implant sticks, progestogen injections, progestogen implants, androgens, anabolic steroids within 6 months of the screening visit.
  • Use oral estrogen, oral progesterone, prasterone (DHEA) or intrauterine progesterone treatment, intravaginal hormonal drugs (ring, cream, gel or tablet), estrogen alone or estrogen/pregnancy within 8 weeks before the screening visit, hormone transdermal drug users.
  • Confirmed depression with poor control under standard treatment or history of diagnosed psychiatric disorder.
  • Those who have participated in or plan to participate in other drug or device clinical trials during the study period within 1 month prior to the screening visit.
  • Laboratory findings suggestive of glutamic-pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST) ≥ 2 times the upper limit of normal, or creatinine ≥ 1.5 times the upper limit of normal.
  • Grade 2 and higher uterine prolapse (cervix reaching labia minora).
  • Transvaginal ultrasound revealed a uterine fibroid ≥ 3 cm in diameter.
  • Endometrial thickness ≥ 4 mm by transvaginal ultrasound, or other comprehensive assessment by the investigator with the possibility of endometrial hyperplasia, deterioration.
  • Current endometrial polyps.
  • Previous endometrial ablation.
  • Patients with vulvar lichen sclerosus.
  • Patients with unexplained vaginal bleeding.
  • Patients who are known to be allergic to the study drug or its ingredients.
  • Patients who have participated in other relevant clinical trials of the investigational drug (prasterone vaginal suppositories).
  • History of past or present drug or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine).

Subjects who are unable to perform the procedures required by the protocol, or any other subjects who are not suitable for this clinical study judged by the investigator.


Trial design

Primary purpose




Interventional model

Parallel Assignment


Quadruple Blind

418 participants in 2 patient groups, including a placebo group

Intravaginal prasterone
Experimental group
6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Drug: intravaginal prasterone
Placebo ovules
Placebo Comparator group
Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
Drug: Placebo ovules

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems